Type 2 diabetes mellitus (T2DM) remains a profound global public health challenge. According to the International Diabetes Federation (IDF) Diabetes Atlas 11th Edition (2025), approximately 589 million adults aged 20–79 years lived with diabetes in 2024, representing nearly  of the world's adult population. Projections indicate that this number could surge to 853 million by 2050, accompanied by global healthcare expenditures exceeding USD 1 trillion. In India, adult diabetes prevalence reached approximately  in 2024, placing millions at risk for severe microvascular and macrovascular complications.

Historically managed as an irreversible disease, the medical landscape shifted following a 2021 international consensus statement endorsed by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and other leading bodies, which formally defined diabetes remission as an  sustained for at least three months without glucose-lowering drugs. While traditional clinical guidelines historically favored low-fat diets, low-carbohydrate healthy-fat (LCHF) interventions have consistently demonstrated superior glycemic recovery, weight loss, and medication reduction. The 2025 ADA Standards of Care officially recognize low-carbohydrate nutrition therapy as an evidence-based medical strategy. Nonetheless, real-world barriers such as a lack of standardized inpatient protocols, physician hesitancy regarding medication titration, and safety concerns persist. This paper outlines an eight-step inpatient clinical protocol utilizing the LCHF model to overcome these hurdles.

LCHF PROTOCOL AND THE DIAREV MODEL

Therapeutic carbohydrate restriction is categorized into clear tiers based on daily consumption limits:

• Very Low-Carbohydrate Ketogenic Diets (VLCKD): Restrict carbohydrates to , actively inducing nutritional ketosis.
• Low-Carbohydrate Diets (LCHF): Prescribe  of total carbohydrates or  of net carbohydrates daily.
• Reduced-Carbohydrate Diets: Permit .

The Disease Reversal Program (DIAREV) model implemented in Odisha utilizes an eight-step structured inpatient framework:

1. Patient registration and clinical intake assessment.
2. Pre-consultation and readiness evaluation.
3. Personalized multidisciplinary counseling.
4. Detoxification initiation and dietary shift to LCHF ().
5. Comprehensive patient education regarding glycemic load.
6. Supervised reduction and tapering of insulin and secretagogues.
7. Integration of targeted yoga and breathing exercises (pranayama).
8. Structured post-discharge follow-up and long-term tracking.

METHODOLOGY AND PATIENT SELECTION

This study reviews an observational case series of  adult participants (aged  years; mean age  years) diagnosed with T2DM who successfully completed the DIAREV inpatient protocol. Baseline diabetes durations ranged from 6 months to over 20 years. Participants presented with numerous cardiometabolic comorbidities, including hypertension (), dyslipidemia (), obesity (), gastrointestinal complaints (), neuropathy (), and prior cardiovascular stenting ().

Table 1: Baseline Demographic and Clinical Characteristics ()

This table summarizes the foundational demographic profile and baseline comorbidity distribution of the participant cohort prior to entering the LCHF intervention.

Implementation of the structured LCHF protocol produced uniform, highly favorable metabolic shifts across the participant cohort.

Table 2: Overall Metabolic Outcomes Before and After LCHF Intervention ()

This table highlights the aggregate changes in body weight, fasting blood sugar, postprandial blood sugar, and HbA1c levels from baseline to post-intervention, supported by high statistical significance.

Note: Statistical significance was evaluated using paired t-tests, verifying exceptional clinical recovery across all parameters.

Table 3: Remission and Clinical Target Achievement

This table displays the proportion of participants who successfully achieved established clinical targets and international standards for diabetes remission following the protocol.

Table 4: Range of Clinical Improvement Observed

This table details the lowest and highest boundary values recorded across the cohort before and after the intervention, illustrating the broad spectrum of metabolic recovery.

Table 5: Summary Statistical Highlights of Key Clinical Parameters

This table outlines the core statistical takeaways and primary efficacy benchmarks derived from the study's primary outcomes.

The clinical results confirm that carbohydrate restriction directly addresses the core pathophysiology of T2DM: chronic hyperinsulinemia and cellular insulin resistance. By cutting down on dietary starches and sugars upstream, postprandial glucose excursions are minimized, which naturally decreases insulin and secretagogue requirements while simultaneously mobilizing visceral and hepatic fat reserves. Unlike conventional pharmaceutical approaches that frequently introduce side effects like weight gain and hypoglycemia, the LCHF model fosters natural metabolic healing. Crucially, significant improvements occurred even in patients suffering from long-term disease durations exceeding 15–20 years, proving that metabolic restoration is possible well beyond the early stages of diagnosis. Sustaining these results over time depends heavily on routine self-monitoring, ongoing clinical support, and practical dietary consistency.

Integrating a structured inpatient Low-Carbohydrate Healthy-Fat protocol provides a safe, highly reproducible framework for achieving T2DM remission. Backed by international consensus recommendations and modern standards of care, targeted carbohydrate restriction helps shift clinical paradigms away from lifelong disease management toward true metabolic recovery.

1. International Diabetes Federation. IDF Diabetes Atlas, 11th ed. 2025 Estimates. Brussels, Belgium: IDF; 2025.
2. Magliano DJ, et al. The global picture of diabetes (NCBI Bookshelf). 2025.
3. IDF Diabetes Atlas projections and health expenditure data. Diabetesatlas.org. 2025.
4. International Diabetes Federation Diabetes Atlas 2025 – India data. IDF; 2025.
5. Sekher TV, et al. Prevalence, awareness, treatment, and control of diabetes in India. Lancet Glob Health. 2025.
6. Pradeepa R, et al. Epidemiology of type 2 diabetes in India: trends and challenges. Diabetes Res Clin Pract. 2021.
7. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44:2438–2444.
8. Schauer PR, et al. Bariatric surgery versus intensive medical therapy. N Engl J Med. 2017.
9. Lean MEJ, et al. Primary care-led weight management for remission (DiRECT). Lancet. 2018.
10. Carter S, et al. Intermittent fasting in T2DM. BMJ Open Diabetes Res Care. 2018.
11. Hallberg SJ, et al. Effectiveness of a low-carbohydrate care model at 1 year. Diabetes Ther. 2018.
12. Athinarayanan SJ, et al. Long-term effects of a continuous remote care intervention. Front Endocrinol. 2019.
13. Goldenberg JZ, et al. Efficacy and safety of low and very low carbohydrate diets. BMJ. 2021;372:m4743.
14. Kahleova H, et al. Plant-based diets in diabetes. Nutrients. 2021.
15. Ludwig DS, et al. Carbohydrate-insulin model revisited. Am J Clin Nutr. 2021.